Search
Human Genetic Research on Susceptibility to SARS-CoV-2 Infection Using Axiom Genotyping Microarrays
Cost effective arrays for rapid epidemiological investigation of SARS-CoV-2 infection (COVID-19) susceptibility in relation to underlying health conditions
A major challenge for healthcare providers and geneticists is to learn how SARS-CoV-2, the coronavirus that causes the COVID-19 disease, interacts with the human genome and to stratify populations in order to understand disease susceptibility, severity, and outcomes.
We have launched our new Axiom Human Genotyping SARS-CoV-2 Research Array.
Axiom genotyping arrays and associated modules for human genotyping research can be used in various aspects of SARS-CoV-2 infection research:
- Susceptibility to COVID-19 and relevant GWAS markers: A large GWAS grid of >800K markers can support research of disease associations including chronic obstructive pulmonary disease (COPD), coronary artery disease traits, and high blood pressure traits across multiple populations to assess risk severity.
- Expression quantitative trait loci (eQTLs): Information about the genetic basis of coronavirus infections in global populations and especially non-Asian Caucasian (CEU) populations is limited. Both ACE2 expression and function may be different in CEU populations.
- Pharmacogenetics research for drug discovery and targets: The large GWAS grid offers the ability to use results from various association studies and thus incorporate genetics into evaluating a large number of druggable targets. Focused arrays with pharmacogenomic content offer the ability to look at a large number of genes involved in drug absorption, distribution, metabolism, and excretion, including the complex CYP genes.
- Pharmacogenetics research for drug-drug and drug-gene interactions: Pharmacogenomics research will be important in understanding the efficacy and dosage of drugs administered as part of the various research studies. The pharmacogenomic research content can help with studies of efficacy and therapeutic effects of treatments that include but are not limited to antivirals and anti-malarial drugs.
- Angiotensin-converting enzyme 2 (ACE2) receptors: The viral receptor protein ACE2 exists on the host cell surface. This is believed to be the mechanism by which the virus enters the body. Study of ACE2 protein requires maximizing the number of X-chromosome markers on the array. There are over 9,000 markers in the ACE2 protein. Any Axiom design can maximize the coverage of these variants.
- Cytokine genes: Inflammatory cytokine genes may influence the function of immunopathological processes in influenza-like illnesses. Study of these genes may help understand the initiation of immune response, controlling viral replication and hypercytokinaemia.
Summary of relevant content in the new Axiom Human Genotyping SARS-CoV-2 Research Array
| Category | Number of Markers* |
| SARS-CoV-2 Susceptibility Research Variant Module | >135,000 |
| SARS-CoV-2 putative receptor variants | >1,200 |
| Signaling pathway variants | >130,000 |
| Variants on X-Chromosome | >60,000 |
| SARS-CoV-2 Severity Research Module – Underlying conditions implicated in severity of SARS-CoV-2 infections | >16,000 |
| Blood phenotypes and blood groups | >1,200 |
| Diabetes | >800 |
| Cardiovascular disease | >1,300 |
| Stroke | >50 |
| Lung function and COPD | >9,000 |
| BMI | >1,000 |
| CKD/RAAS | >450 |
| Asthma | >500 |
| SARS-CoV-2 Immune Response and Therapeutic Treatment Research Variants Module | >24,000 |
| ADME and protein markers for druggable targets | >6,000 |
| Immunoglobulin and miRNA markers for vaccine research | >12,000 |
| HLA/KIR markers for immune response research after vaccination | >9,000 |
| Multi-ethnic Genome Wide Association Study (GWAS) Grid | >725,000 |
| ACMG 59 Variants | >6,000 |
| Functional coding-region variants including eQTL and loss-of-function variants | >24,000 |
A marker may appear in more than one category.
For Research Use Only. Not for use in diagnostic procedures.